its actually undervalued as when FDA approval was announced it was almost double the price....
no doubt the long term price action contributed to the sell down and resistance on this event in April...
- Forums
- ASX - By Stock
- Ann: NEXTSTELLIS FDA exclusivity & phase III data published
MYX
mayne pharma group limited
Add to My Watchlist
0.40%
!
$5.02

its actually undervalued as when FDA approval was announced it...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.02 |
Change
0.020(0.40%) |
Mkt cap ! $407.8M |
Open | High | Low | Value | Volume |
$5.05 | $5.09 | $4.96 | $774.1K | 154.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 3317 | $4.99 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.04 | 1291 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1317 | 4.990 |
1 | 1000 | 4.980 |
1 | 1000 | 4.960 |
1 | 1291 | 4.950 |
1 | 870 | 4.940 |
Price($) | Vol. | No. |
---|---|---|
5.040 | 1291 | 1 |
5.060 | 6210 | 4 |
5.080 | 1291 | 1 |
5.090 | 1100 | 2 |
5.100 | 1875 | 2 |
Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
SPONSORED BY The Market Online